September 30, 2025
4 min watch
LAS VEGAS — In this Healio Video Perspective, Tarek S. Hassan, MD, professor of ophthalmology at Oakland University William Beaumont Hospital, discusses the results of a phase 2a study of AVD-104 for geographic atrophy.
Eighty-four percent of eyes that received a clinical dose of AVD-104 (Aviceda Therapeutics) experienced visual improvement of five or more letters after one intravitreal injection at 3 months. AVD-104 also slowed the growth of GA lesions by nearly 50%.
“The entire phase 2a trial showed overall anatomic and functional improvement with AVD-104 for treating GA in AMD,” Hassan, chief development officer of Aviceda, told Healio.
He said the results are being further explored in a phase 2b/3 trial.
“We anticipate more excitement from this potentially valuable next-generation treatment for geographic atrophy,” Hassan said.
Sources/Disclosures
Source:
Hassan T. AVD-104: Glycoimmune modulation in the management of geographic atrophy from AMD. Presented at: Clinical Trials at the Summit; June 21, 2025; Las Vegas.
Disclosures:
Hassan reports being an employee of Aviceda Therapeutics.
